Cambiar Investors’s Halozyme HALO Stock Holding History

Cambiar Investors’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.81M	Sell	23,139 -122	-0.5%	-$8.32K	0.08%	109
2026 Q1	$1.5M	Buy	+23,261	New	+$1.64M	0.07%	113

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Cambiar Investors's HALO Position: Q2 2026 in Review

Cambiar Investors reduced its Halozyme (HALO) stake by 0.52% in Q2 2026, selling an estimated $8.32K and leaving 23,139 shares worth $1.81M. The position accounts for 0.08% of the portfolio, ranked #109.

Cambiar Investors first reported a position in HALO in Q1 2026 and has held it in 2 quarters since. 674 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

Cambiar Investors held 23,139 shares of Halozyme worth $1.81M as of Q2 2026.
Cambiar Investors sold 122 Halozyme shares in Q2 2026, an estimated $8.32K.
Halozyme made up 0.08% of Cambiar Investors's portfolio in Q2 2026, its #109 holding.
Cambiar Investors first reported a position in Halozyme in Q1 2026 and has held it in 2 quarters since.
674 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Cambiar Investors's 13F filing for Q2 2026, filed 31 Jul 2026.